



# Improving Care Transitions in Patients with Venous Thromboembolism

# Objectives & Agenda

## Session Objectives

- Understand the prevalence, burden, challenges and risks associated with patients with venous thromboembolism (VTE)
- Takeaway key learnings on how to better manage transitions of care for patients with VTE

## Agenda Topics



Prevalence & Burden  
of Disease



Treatment &  
Guidelines



Patient Flow &  
Challenges



Strategies for  
Improved Care

# Disclaimers



This promotional educational activity is brought to you by Janssen Pharmaceuticals, Inc., and is not certified for continuing medical education. The panelists are paid consultants for Janssen Pharmaceuticals, Inc. The panelists are participating on behalf of Janssen Pharmaceuticals, Inc., and must share information in compliance with FDA requirements. The views, thoughts and opinions expressed by the panelists belong solely to the panelists and not to AMGA or Janssen Pharmaceuticals, Inc.

Any protocols discussed by the panelists were not created in collaboration with Janssen Pharmaceuticals, Inc. They were created by the listed institution only. Janssen does not endorse or recommend the use of any particular protocol. These protocols are not intended to replace the independent medical or professional judgment of physicians or other healthcare providers.



This material is being presented by healthcare professionals in collaboration with AMGA. Panelists are paid consultants of Janssen Pharmaceuticals, Inc.



## Presenters & Panelists

**John Cuddeback, MD, PhD**  
Chief Medical Informatics Officer  
AMGA

**Laura Balsamini, PharmD, BCPS**  
National Vice President, Pharmacy Services  
Summit Health – Basking Ridge, NJ

**Paige Christensen, NP**  
Associate Medical Director of System Anticoagulation and  
Thrombosis, Medical Specialties Clinical Program  
Intermountain Healthcare – Salt Lake City, UT

# Prevalence & Burden of VTE



Approximately **900,000** patients will have a VTE every year in the US<sup>1</sup>

Up to **100,000** deaths are due to VTE, primarily PE.<sup>2</sup>

Upon presentation, of those who experience a PE, 1 in 4 will die.<sup>3</sup>

**NEARLY 1 in 3\***



patients who have had a DVT or PE

**WILL HAVE A RECURRENT VTE.**<sup>4,5</sup>



**MORE THAN 1 in 5 VTEs**

are due to a recurrent or recent hospitalization in medically ill patients.<sup>6</sup>



**The risk of clots remains after hospital discharge.**

**67%** of VTEs occur within the **FIRST 30 DAYS** after hospital discharge.<sup>7</sup>

\*Within 10 years

DVT, deep vein thrombosis; PE, pulmonary embolism; VTE, venous thromboembolism

**References:** 1. CDC. Data and statistics on venous thromboembolism. Accessed November 24, 2021. <https://www.cdc.gov/ncbddd/dvt/data.html>. 2. Rathbun S. *Circulation*. 2009;119:e480–e482. 3. Heit JA. Venous thromboembolism: disease burden, outcomes and risk factors. *J Thromb Haemost*. 2005;3(8):1611-1617. 4. Heit JA. Epidemiology of venous thromboembolism. *Nat Rev Cardiol*. 2015;12(8):464-74. doi:10.1038/nrcardio.2015.83. 5. What is Venous Thromboembolism? CDC. Reviewed February 7, 2020. Accessed November 24, 2021. <https://www.cdc.gov/ncbddd/dvt/facts.html>. 6. Heit JA, O'Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. *Arch Intern Med*. 2002;162(11):1245-1248. doi:10.1001/archinte.162.11.1245. 7. Spencer FA, Lessard D, Emery C, Reed G, Goldberg RJ. Venous thromboembolism in the outpatient setting. *Arch Intern Med*. 2007;167(14):1471-1475.




This material is being presented by healthcare professionals in collaboration with AMGA. Panelists are paid consultants of Janssen Pharmaceuticals, Inc.

# VTE Treatment & Guidelines



- Anticoagulation therapy is a delicate balance<sup>1</sup> →
- There is often the discontinuity of hospital discharge, early in the process<sup>2</sup> ---
- Treatment must be maintained over a long time, in multiple settings, with multiple providers<sup>3,4</sup>



**VTE Guidelines**

|      |      |
|------|------|
| ACCP | ESC  |
| ACP  | NATF |
| ASH  | ISTH |

**Care Process Model**  
Intermountain Healthcare

**References:** 1. Wells PS, et al. *JAMA*. 2014;311(7):717-728. doi:10.1001/jama.2014.65. 2. Jaffray, et al. *Thrombosis Research*. 2018; 163:146-152. 3. Ortel, et al. *Blood Adv*. 2020;4(19):4693-4738. 4. Lenchus JD. *Adv Ther*. 2016;33(1):29-45.

ACCP American College of Chest Physicians  
 ACP American College of Physicians  
 ASH American Society of Hematology  
 ESC European Society for Cardiology  
 NATF North America Thrombosis Forum  
 ISTH International Society on Thrombosis and Haemostasis



This material is being presented by healthcare professionals in collaboration with AMGA. Panelists are paid consultants of Janssen Pharmaceuticals, Inc.

# AMGA VTE Care Transitions – Roundtables & Research



- **Roundtables:** AMGA recently conducted roundtables with 12 member organizations, selected to share their VTE expertise



**VTE Expertise**

- Clinical protocols
- Care team structures
- Risk assessment tools
- Anticoagulation clinics


- Advocate Aurora Health
- Billings Clinic
- Cleveland Clinic
- Geisinger
- HealthPartners Park Nicollet
- Henry Ford Health System
- Intermountain Healthcare
- Lehigh Valley Health Network
- Mercy (St. Louis)
- Ochsner Health System
- Permanente Medical Group
- University of Wisconsin Health

- **Research:** To understand the flow of patients with VTE, AMGA analyzed adjudicated claims data from AMGA member organizations participating in the Collaborative for Performance Excellence, a partnership between AMGA and Optum



This material is being presented by healthcare professionals in collaboration with AMGA. Panelists are paid consultants of Janssen Pharmaceuticals, Inc.

# VTE Care Transitions – Patient Flow



This material is being presented by healthcare professionals in collaboration with AMGA. Panelists are paid consultants of Janssen Pharmaceuticals, Inc.

Disclaimer: The data represented in this figure were prepared by AMGA Analytics who take full responsibility for the accuracy of the results. The figure is based on AMGA's analysis of Optum adjudicated claims data for 2018 and 2019.

# Strategies for Improving Care Transitions in Patients with VTE



Multidisciplinary, multispecialty care team



Protocols



Provider Communication



Medication Access & Affordability



Anticoagulation Clinic



Patient Education



Follow-Up Process



This material is being presented by healthcare professionals in collaboration with AMGA. Panelists are paid consultants of Janssen Pharmaceuticals, Inc.

# Thank You!



This material is being presented by healthcare professionals in collaboration with AMGA.  
Panelists are paid consultants of Janssen Pharmaceuticals, Inc.

© Janssen Pharmaceuticals, Inc. 2021 11/21 cp-253048v2

[amga.org](http://amga.org)